A Joint Study of Features and Treatment of Urogenital Disorders in Japan and People's Republic of China
Grant-in-Aid for Overseas Scientific Survey.
|Allocation Type||Single-year Grants|
|Research Institution||Department of Urology, Tokyo Medical and Dental University|
OSHIMA Hiroyuki Professor of Urology, Tokyo Medical and Dental University, 医学部・泌尿器科, 教授 (60013934)
那 彦群 北京医科大学, 副教授
郭 慶禄 北京医科大学, 教授
〓 方六 北京医科大学, 教授
KIHARA Kzunori Assistant Professor of Urology, 医学部泌尿器科, 助手 (40161541)
GOTOH Syuichi Instructor of Urology, 医学部泌尿器科, 講師 (30143580)
FUKUI Iwao Associate Professor of Urology, 医学部泌尿器科, 助教授 (90014232)
|Project Period (FY)
Completed(Fiscal Year 1990)
|Keywords||Joint study / Japan / China / Chemotherapy / Urogenital cancer / Urogenital anomaly|
A joint study of features and treatment of urogenital disorders was started in May, 1990. Mean inpatients number is 400 per year at urological service, Beijing Medical School. Purposes of this study are to evaluate the neoadjuvant chemotherapy of invasive bladder cancer, castration plus chemotherapy for the advanced prostatic cancer and the incidence of congenital anomaly.
Results are as follows :
1) For neoadjuvant chemotherapy of invasive bladder cancer, 8 patients were treated with CDDP arterial instillation method. Partial tumor regression was revealed in all patients with surgically resected materials. It seems that this therapy is also available in China because of tumor regression effect with low toxicity.
2) 7 cases of prostatic cancer with bone metastasis were treated with castration and IFAP (Ifosphamide, 5FU, Adriacin and CDDP) chemotherapy. This combination therapy is effective with not only pain relief but also accelerated reduction of serum tumor markers levels. Long follow up is needed.
3) The incidence of congenital anomaly in inpatients is 8% in both institutes. And it is also the same situation that undescended testis and urethral hypospadia are the most common congenital anomalies.
Research Output (3results)